Details

Autor(en) / Beteiligte

• Meckbach, Diana
• Bauer, Jürgen
• Pflugfelder, Annette
• Meier, Friedegund
• Busch, Christian
• Eigentler, Thomas K
• Capper, David
• von Deimling, Andreas
• Mittelbronn, Michel
• Perner, Sven
• Ikenberg, Kristian
• Hantschke, Markus
• Büttner, Petra
• Garbe, Claus
• Weide, Benjamin
• Haass, Nikolas K.

Titel

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma

Ist Teil von

• PloS one, 2014-01, Vol.9 (1), p.e86194-e86194

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2014

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, histological subtype as well as mitotic rate. The mutational rate was 36.7% in patients with disease-free course and 51.7% in those with subsequent distant metastasis (p = 0.031). No difference in overall survival (p = 0.119) but a trend for worse distant-metastasis-free survival (p = 0.061) was observed in BRAF mutant compared to BRAF wild-type patients. Independent prognostic factors for overall survival were tumor thickness, mitotic rate and ulceration. An interesting significant prognostic impact was observed in patients with tumor thickness of 1 mm or less, with the mutation present in 6 of 7 patients dying from melanoma. In conclusion, no significant survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma but an increasing impact of the mutational status was observed in the subgroup of patients with tumor thickness of 1 mm or less. A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies.